Core Viewpoint - The stock of Xinwei Medical-B (06609) has risen over 10%, currently trading at HKD 56.75, with a transaction volume of HKD 13.4465 million, driven by positive expectations regarding its upcoming interim results [1] Financial Performance - Xinwei Medical anticipates a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025, marking a turnaround from a loss to a profit [1] - The increase in revenue is primarily attributed to the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] Cost Management - Effective cost control measures have led to a decrease in overall expense ratios for the group [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] Financial Assets - There has been an increase in the fair value gains of financial assets measured at fair value through profit or loss [1]

Core Viewpoint - The stock of Heartway Medical-B (06609) has risen over 10%, currently trading at HKD 56.75, with a transaction volume of HKD 13.4465 million, following the announcement of an upcoming board meeting to review and approve the interim results for the six months ending June 30, 2025 [1] Financial Performance - Heartway Medical anticipates a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025, marking a turnaround from a loss to a profit [1] - The expected profit increase is primarily driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] Cost Management - Effective cost control measures have led to a decrease in the overall expense ratio for the group [1] - Changes in the research and development phase of the group's projects have resulted in reduced R&D expenditures [1] Financial Assets - There has been an increase in the fair value gains of financial assets measured at fair value through profit or loss [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to improved profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains from financial assets measured at fair value through profit or loss [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of newly launched hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to the company's profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains on financial assets measured at fair value through profit or loss [1]